What is the standard of care for locally advanced Bladder Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Bladder Cancer (NCCN Guidelines)

Locally advanced bladder cancer typically refers to Stage IIIA, IIIB, and IVA disease — tumors that have invaded deeply into the bladder muscle or spread to nearby lymph nodes, but haven't yet spread to distant organs. Here's what the current standard of care involves:

PRIMARY TREATMENT OPTIONS

According to the NCCN Guidelines Version 2.2025, doctors typically choose between two main approaches for locally advanced disease:

1. Radical Cystectomy (Surgical Removal of the Bladder)

• Removal of the entire bladder, surrounding tissues, and pelvic lymph nodes
• Often combined with neoadjuvant chemotherapy (chemotherapy given before surgery to shrink the tumor)
• This is considered the gold standard for fit patients who can tolerate surgery

2. Bladder-Preserving Chemoradiotherapy

• Combined chemotherapy and radiation therapy delivered together
• Allows patients to keep their bladder
• Best suited for patients with:
  • Tumors smaller than 6 cm
  • No severe hydronephrosis (kidney swelling)
  • No extensive carcinoma in situ (CIS — widespread pre-cancerous cells)
  • Ability to have complete tumor removal with TURBT (transurethral resection)

NEOADJUVANT CHEMOTHERAPY (Before Surgery)

For Stage IIIB disease (tumors with positive lymph nodes), the NCCN Guidelines emphasize that neoadjuvant chemotherapy significantly improves outcomes:

• For cN1 disease (single positive lymph node): Complete pathologic downstaging (tumor completely eliminated) occurred in 39% of patients who received chemotherapy versus only 5% who didn't
• For cN2-3 disease (multiple positive lymph nodes): Downstaging rates were 27% versus 3%
• Overall survival was substantially improved with chemotherapy treatment

TREATMENT AFTER INITIAL THERAPY

If complete response is achieved:

• Surveillance (careful monitoring) or
• Consolidation cystectomy (surgery to remove bladder) or
• Consolidation chemoradiotherapy (additional treatment)

If partial response occurs:

• Reassess tumor status 2-3 months after treatment
• Consider additional surgery or systemic therapy depending on what remains

If disease progresses:

• Treat as metastatic disease with additional systemic therapy

ADJUVANT THERAPY (After Surgery)

For patients undergoing cystectomy, additional treatment may be recommended based on pathologic findings:

• Adjuvant cisplatin-based chemotherapy (preferred) if high-risk features are present (pT3, pT4a, or positive lymph nodes)
• Checkpoint inhibitor immunotherapy (nivolumab or pembrolizumab) as an alternative
• Adjuvant radiation therapy in selected cases with very high-risk features

KEY CLINICAL CONSIDERATIONS

Cisplatin Eligibility Assessment:

• Kidney function (GFR — glomerular filtration rate) must be adequate for cisplatin chemotherapy
• For borderline kidney function, a timed urine collection may be done for more accurate assessment

Molecular/Genomic Testing:

• Recommended for Stage IIIB and IVA disease to identify:
  • FGFR3 alterations (may qualify for targeted therapy with erdafitinib)
  • HER2 overexpression (may qualify for targeted therapy with fam-trastuzumab deruxtecan)
  • PD-L1 status (helps determine immunotherapy eligibility)

IMPORTANT PATIENT-SPECIFIC FACTORS

Your oncologist will personalize treatment based on:

• Your overall health and ability to tolerate chemotherapy/surgery/radiation
• Kidney function
• Age and comorbidities (other health conditions)
• Tumor characteristics and extent
• Your preferences regarding bladder preservation

---

Questions to Ask Your Healthcare Team

1. What is my specific stage and what does that mean for my treatment options?
2. Am I a candidate for neoadjuvant chemotherapy, and if so, what regimen would you recommend?
3. What are the pros and cons of cystectomy versus chemoradiotherapy for my situation?
4. Has molecular/genomic testing been done on my tumor, and do the results change my treatment options?
5. What is my kidney function, and does that affect my eligibility for cisplatin-based chemotherapy?
6. What follow-up surveillance plan would you recommend after initial treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.